Literature DB >> 7576001

Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies.

T L Vassilev1, I L Bineva, G Dietrich, S V Kaveri, M D Kazatchkine.   

Abstract

The beneficial effect of intravenous immunoglobulin (IVIg) therapy in patients with autoimmune diseases is at least partially dependent on the content in IVIg of antibodies capable of interacting with variable regions (idiotypes) of autoantibodies. In the present study, we have evaluated the antibody activity to a panel of self and environmental antigens of IVIg preparations and their dimer-enriched fractions. Dimers were either obtained by affinity chromatography of IVIg on Sepharose-bound F(ab')2 fragments of IVIg or by size exclusion gel filtration chromatography of IVIg. Enrichment of IVIg in dimers was found to be associated with an increase in the antibody activity against self-antigens as compared with unchromatographed IVIg. Our findings extend previous observations on enhanced autoantibody content of the affinity chromatography-separated 'connected' fraction of IVIg and suggest that therapeutic preparations of IVIg enriched in dimers may be obtained by size exclusion chromatography. Separation by size increases the feasibility of industrial-scale preparation of IVIg with high dimer content that are endowed with high potential immunomodulatory activity in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576001     DOI: 10.1006/jaut.1995.0032

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

1.  Intravenous immunoglobulins. Current understanding and future directions.

Authors:  S Jolles; S V Kaveri; J Orange
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 2.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 3.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

4.  Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block.

Authors:  John G Routsias; Nikolaos C Kyriakidis; Deborah M Friedman; Carolina Llanos; Robert Clancy; Haralampos M Moutsopoulos; Jill Buyon; Athanasios G Tzioufas
Journal:  Arthritis Rheum       Date:  2011-09

5.  Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.

Authors:  J L Teeling; E R De Groot; A J Eerenberg; W K Bleeker; G Van Mierlo; L A Aarden; C E Hack
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 6.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

7.  In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations.

Authors:  F Dhainaut; P-O Guillaumat; H Dib; G Perret; A Sauger; C de Coupade; M Beaudet; M Elzaabi; L Mouthon
Journal:  Vox Sang       Date:  2012-09-25       Impact factor: 2.144

8.  Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

Authors:  Christian Ritter; Ilja Bobylev; Helmar C Lehmann
Journal:  J Neuroinflammation       Date:  2015-08-14       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.